C4 Therapeutics, Inc. · 10 hours ago
Vice President, DMPK
Watertown, MA
Full-time
Onsite
Director/Executive
$321K/yr - $355K/yr
15+ years expC4 Therapeutics is seeking a visionary Vice President of Drug Metabolism & Pharmacokinetics (DMPK) to lead the strategic direction of their DMPK organization. The role involves overseeing the development and execution of DMPK strategies, collaborating across various scientific domains, and ensuring data-driven decision making to advance targeted protein degraders.
Health DiagnosticsMedicalTherapeutics
Responsibilities
Establish and communicate a compelling DMPK vision tailored to targeted protein degraders, informed by C4T’s clinical, translational, and discovery insights
Define portfolio‑wide DMPK strategy spanning discovery, candidate selection, IND‑enabling pharmacokinetics, and Phase 1 clinical translation
Champion innovation in mechanistic and translational PK/PD approaches to advance degrader program success
Serve as a senior advisor to executive leadership on DMPK‑related program risks, decision points, and timelines
Oversee all in vitro and in vivo ADME, PK, PK/PD and toxicology activities supporting degrader optimization and program advancement
Drive development of predictive PK/PD, human PK, and dose projection models for degrader molecules
Direct IND‑enabling DMPK packages, including: Cross‑species PK studies, Metabolism and metabolite identification, Plasma‑protein binding and distribution studies, DDI risk assessments (CYP inhibition/induction, transporter studies), Bioanalytical method development
Guide interpretation of clinical PK findings and integration back into discovery and early development strategies
Partner deeply with Medicinal Chemistry to guide degrader design based on PK liabilities, exposure drivers, and mechanistic ADME insights
Collaborate with Pharmacology and Translational Medicine to establish PK/PD relationships, biomarker integration, and exposure‑response strategies
Work with CMC to support formulation, developability assessments, and clinical supply readiness
Engage Clinical Development and Clinical Pharmacology to define early clinical PK strategies and influence dose‑escalation planning
Define, optimize and streamline workflows to fit portfolio needs and budget
Lead, mentor, and develop team of internal and external scientists (CRO and consultants)
Build a culture of scientific rigor, innovation, proactive partnership, and operational excellence
Manage external CRO relationships to ensure quality, timeliness, and strategic alignment with program goals
Oversee departmental budget, resource planning, and vendor strategy
Represent C4T in scientific and regulatory interactions as the DMPK subject matter expert
Participate in scientific forums, publish impactful research, and maintain awareness of emerging tools and trends in TPD and ADME science
Qualification
Required
A PhD in Pharmacokinetics, Pharmacology, Pharmaceutical Sciences, Biochemistry, or related field required with at least fifteen years of industry experience in DMPK/ADME/PK, with broad capabilities across pharmacokinetics, pharmacodynamics, ADME, human PK modeling, PK/PD determinations, and clinical pharmacology that demonstrate expert knowledge of pharmacokinetic and drug metabolism principles for small molecule drug development
Demonstrated experience supporting discovery‑to‑IND and IND‑to‑clinic transitions, including strong translational experience working with products of this nature; understanding what happens in the clinic, how to anticipate these risks and needs, and the impact of current and evolving FDA guidance on these activities
Demonstrated history of successful DMPK team management, including experience with coaching, delegation, employee development, and performance management
Proven track record in innovation and creativity, critical scientific thinking and analysis, with a deep level of curiosity and understanding of new technologies and cutting-edge approaches to address DMPK issues
Strong track record of independently authoring and providing regulatory guidance to team members on technical reports/summaries, suitable for inclusion in registration dossiers, as well as managing correspondence with regulatory authorities
Preferred
Prior experience with complex modalities (e.g., beyond‑Ro5, bifunctional small molecules, TPD/PROTACs)
Company
C4 Therapeutics, Inc.
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives.
51-200 employees
H1B Sponsorship
C4 Therapeutics, Inc. has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (1)
2024 (1)
2023 (1)
2022 (3)
2020 (1)
Funding
Current Stage
Public CompanyTotal Funding
$423.8MKey Investors
RA Capital ManagementBetta PharmaceuticalsPerceptive Advisors
2025-10-16Post Ipo Equity· $125M
2023-05-30Post Ipo Equity· $25M
2022-08-15Post Ipo Equity
Leadership Team
Kendra Adams
Chief Financial Officer
Recent News
BioWorld Financial Watch
2026-01-16
Company data provided by crunchbase